Baader Bank Aktiengesellschaft Has $3.90 Million Position in Zoetis Inc. $ZTS

Baader Bank Aktiengesellschaft raised its holdings in Zoetis Inc. (NYSE:ZTS) by 647.5% in the third quarter, Holdings Channel.com reports. The fund owned 26,834 shares of the company’s stock after acquiring an additional 23,244 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Zoetis were worth $3,903,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC raised its holdings in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares in the last quarter. NewSquare Capital LLC boosted its holdings in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares in the last quarter. Financial Consulate Inc. acquired a new position in Zoetis during the third quarter worth $39,000. SJS Investment Consulting Inc. raised its holdings in Zoetis by 1,606.3% during the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC acquired a new stake in shares of Zoetis in the third quarter worth about $42,000. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ZTS. The Goldman Sachs Group raised Zoetis to a “buy” rating in a report on Monday, December 15th. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 target price (down previously from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. HSBC set a $140.00 price target on Zoetis in a report on Wednesday, December 10th. JPMorgan Chase & Co. dropped their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Finally, Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $152.45.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $128.13 on Wednesday. The company has a market cap of $56.47 billion, a price-to-earnings ratio of 21.57, a PEG ratio of 2.20 and a beta of 0.96. The business has a 50 day moving average price of $124.03 and a 200 day moving average price of $135.84. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.00.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.